spirogermanium has been researched along with Adenocarcinoma in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (62.50) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, RB; Green, M; Henderson, E; Rafla, S; Schulman, P | 1 |
| Castronovo, FP; DeLuca, SA; Rhea, JT | 1 |
| Budman, DR; Coleman, M; Ginsberg, S; Hanson, J; Perry, M; Schein, P; Weinberg, V; Wood, W | 1 |
| Asbury, RF; Cnaan, A; Haller, DG; Harris, J; Johnson, L; Zaentz, SD | 1 |
| Asbury, R; Dutcher, JP; Haller, DG; Novik, Y; Ryan, LM; Schutt, A | 1 |
| Slavik, M; Williamson, SK | 1 |
| Blumenstein, B; Costanzi, JH; Crawford, ED; Saiers, JH; Slavik, M | 1 |
| Chiuten, DF; Dhingra, HM; Holoye, PY; Murphy, WK; Spitzer, G; Umsawasdi, T; Valdivieso, M | 1 |
3 trial(s) available for spirogermanium and Adenocarcinoma
| Article | Year |
|---|---|
An Eastern Cooperative Oncology Group phase II study of single agent DHAD, VP-16, aclacinomycin, or spirogermanium in metastatic pancreatic cancer.
Topics: Aclarubicin; Adenocarcinoma; Adjuvants, Immunologic; Antineoplastic Agents; Etoposide; Female; Humans; Male; Mitoxantrone; Organometallic Compounds; Pancreatic Neoplasms; Spiro Compounds; Survival Rate | 1994 |
Phase II protocol for the evaluation of new treatments in patients with advanced gastric carcinoma: results of ECOG 5282.
Topics: Aclarubicin; Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Etoposide; Female; Humans; Male; Mitoxantrone; Organometallic Compounds; Spiro Compounds; Stomach Neoplasms | 1999 |
Phase I evaluation of spirogermanium and 5-fluorouracil in colorectal carcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Evaluation; Fluorouracil; Humans; Male; Middle Aged; Organometallic Compounds; Spiro Compounds | 1991 |
5 other study(ies) available for spirogermanium and Adenocarcinoma
| Article | Year |
|---|---|
Phase II trial of spirogermanium in advanced renal cell carcinoma: a Cancer and Leukemia Group B study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Drug Evaluation; Female; Germanium; Humans; Kidney Neoplasms; Male; Middle Aged; Organometallic Compounds; Spiro Compounds | 1984 |
The effects of chemotherapy on bony metastases as measured by quantitative skeletal imaging.
Topics: Adenocarcinoma; Antineoplastic Agents; Bone and Bones; Bone Neoplasms; Colonic Neoplasms; Diphosphonates; Fluorouracil; Germanium; Humans; Male; Middle Aged; Organometallic Compounds; Radionuclide Imaging; Spiro Compounds; Technetium; Technetium Compounds; Time Factors | 1983 |
Phase II trial of spirogermanium in breast adenocarcinoma: a Cancer and Leukemia Group B Study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Drug Evaluation; Female; Germanium; Humans; Middle Aged; Organometallic Compounds; Spiro Compounds | 1982 |
Phase II study of spirogermanium in advanced adenocarcinoma of the prostate: a Southwest Oncology Group Study.
Topics: Adenocarcinoma; Drug Evaluation; Humans; Male; Organometallic Compounds; Prostatic Neoplasms; Spiro Compounds | 1987 |
Phase II study of spirogermanium in advanced (extensive) non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Drug Evaluation; Female; Germanium; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organometallic Compounds; Spiro Compounds | 1986 |